SERPINA4 Human
Description
Product Specs
To generate a working stock solution, it is advisable to add deionized water to the lyophilized pellet, aiming for a concentration of roughly 0.5 mg/ml. Allow adequate time for the pellet to completely dissolve. It's essential to note that SERPINA4 is not sterile in its lyophilized form. Prior to using it for cell culture applications, ensure sterility by filtering the reconstituted protein through an appropriate sterile filter.
Product Science Overview
Kallistatin consists of three folded β segments and eight helical structures, containing two functional domains: an active site and a heparin-binding site . It functions primarily as an inhibitor of tissue kallikrein, a serine protease involved in the kinin-kallikrein system, which regulates blood pressure, inflammation, and coagulation .
- Inhibition of Tissue Kallikrein: Kallistatin specifically inhibits tissue kallikrein, thereby regulating the production of kinins, which are peptides that influence blood pressure and inflammation .
- Anti-Angiogenic and Anti-Tumor Properties: Kallistatin has been shown to inhibit angiogenesis (the formation of new blood vessels) and tumor growth, making it a potential therapeutic target for cancer treatment .
- Vascular Remodeling: Kallistatin plays a role in vascular remodeling, which is crucial for maintaining vascular homeostasis and function .
Recombinant human kallistatin is produced using advanced biotechnological methods. It is typically expressed in a mouse myeloma cell line (NS0) and purified to high levels of purity . The recombinant form retains the functional properties of the native protein, making it useful for research and potential therapeutic applications.
Given its role in inhibiting angiogenesis and tumor growth, kallistatin is being explored for its therapeutic potential in cancer treatment. Additionally, its ability to regulate blood pressure and inflammation positions it as a candidate for treating cardiovascular diseases and inflammatory conditions .
